{
  "disease": "esophageal cancer",
  "original_target": null,
  "failed_trials_count": 5,
  "failure_patterns": {
    "safety_issues": 0,
    "efficacy_issues": 0,
    "recruitment_issues": 4,
    "business_reasons": 0,
    "other_reasons": 1,
    "unknown": 0
  },
  "side_effects_analysis": {
    "safety_terminations_count": 0,
    "safety_terminations": [],
    "why_stopped_categories": {
      "safety_related": 0,
      "efficacy_related": 0,
      "business_related": 0,
      "other": 5
    },
    "why_stopped_details": {
      "safety_related": [],
      "efficacy_related": [],
      "business_related": [],
      "other": [
        "IRB Approval Lapse - working on resubmission",
        "The study was stopped earlier than anticipated due to slow accrual",
        "adapted protocol with changed outcome measures, changed recruitment number, no submission to ethical board review",
        "Poor accruals",
        "low accrual rate"
      ]
    },
    "adverse_events_summary": {},
    "side_effects_patterns": {
      "patterns": [],
      "drug_classes_affected": [],
      "organ_systems": []
    },
    "repurposing_opportunities": []
  },
  "failure_analysis": {
    "failed_drugs_analysis": [
      {
        "drug_name": "Nivolimumab+Carboplatin/paclitaxel+Radiation",
        "mechanism": "Immune checkpoint inhibition combined with chemotherapy and radiation",
        "failure_type": "other",
        "biological_insight": "Slow patient accrual suggests challenges in patient selection or eligibility criteria, which may indicate a lack of suitable candidates for this combination therapy."
      },
      {
        "drug_name": "\"Endostar\"",
        "mechanism": "Anti-angiogenic therapy",
        "failure_type": "other",
        "biological_insight": "Low accrual rate may suggest limited interest or perceived effectiveness among oncologists and patients, indicating potential issues with the drug's efficacy in a heterogeneous cancer population."
      },
      {
        "drug_name": "Liposo",
        "mechanism": "Chemotherapy agent (liposomal formulation)",
        "failure_type": "other",
        "biological_insight": "The low accrual rate indicates potential concerns regarding the drug's tolerability or effectiveness, which may not have been compelling enough for patients to enroll."
      },
      {
        "drug_name": "cisplatin",
        "mechanism": "Alkylating agent that interferes with DNA replication",
        "failure_type": "other",
        "biological_insight": "Cisplatin is known for its toxicity; the low accrual may reflect patient reluctance due to expected side effects or previous negative experiences with similar treatments."
      },
      {
        "drug_name": "Gimeracil and Oteracil Potassium (Tegafur)",
        "mechanism": "Antimetabolite that inhibits DNA synthesis",
        "failure_type": "other",
        "biological_insight": "The combination with other agents may not have shown a clear benefit, leading to low patient interest and recruitment challenges."
      }
    ],
    "disease_insights": "The failures indicate that esophageal cancer may have a complex biology that is not adequately addressed by current therapeutic strategies, highlighting the need for more personalized approaches.",
    "failed_pathways": [
      "immune checkpoint pathways",
      "angiogenesis pathways",
      "DNA repair pathways"
    ],
    "alternative_mechanisms": [
      "targeted therapies against specific mutations (e.g., HER2, EGFR)",
      "novel immunotherapies (e.g., CAR-T cell therapy)",
      "combination therapies with novel agents targeting metabolic pathways"
    ],
    "key_biological_challenges": [
      "heterogeneity of esophageal cancer subtypes",
      "development of resistance to existing therapies",
      "patient selection and recruitment difficulties"
    ]
  },
  "repurposing_candidates": [
    {
      "drug": "Irinotecan",
      "total_trials": 5,
      "completed": 3,
      "failed": 0,
      "ongoing": 2,
      "phases": [
        "PHASE3",
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT06304974",
        "NCT00590031",
        "NCT05319730",
        "NCT01084330",
        "NCT03797625"
      ],
      "repurposing_score": 100.0,
      "chembl_id": "CHEMBL481",
      "max_phase": 3,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "Paclitaxel",
      "total_trials": 3,
      "completed": 2,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT05319730",
        "NCT02539225",
        "NCT02429622"
      ],
      "repurposing_score": 90.0,
      "chembl_id": "CHEMBL428647",
      "max_phase": "4.0",
      "resolution_source": "chembl_exact"
    },
    {
      "drug": "fluorouracil",
      "total_trials": 3,
      "completed": 2,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT00425425",
        "NCT01212822",
        "NCT00022139"
      ],
      "repurposing_score": 90.0,
      "chembl_id": "CHEMBL185",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "Capecitabine",
      "total_trials": 2,
      "completed": 1,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT02678182",
        "NCT01843725"
      ],
      "repurposing_score": 80.0,
      "chembl_id": "CHEMBL1773",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "Docetaxel",
      "total_trials": 2,
      "completed": 1,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT05383482",
        "NCT01084330"
      ],
      "repurposing_score": 80.0,
      "chembl_id": "CHEMBL3545252",
      "max_phase": "4.0",
      "resolution_source": "chembl_exact"
    },
    {
      "drug": "oxaliplatin",
      "total_trials": 2,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT00425425",
        "NCT01212822"
      ],
      "repurposing_score": 80.0,
      "chembl_id": "CHEMBL414804",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "BT1718",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT03486730"
      ],
      "repurposing_score": 70.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "Nedaplatin",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT02429622"
      ],
      "repurposing_score": 70.0,
      "chembl_id": "CHEMBL3137685",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "paclitaxel",
      "total_trials": 4,
      "completed": 1,
      "failed": 1,
      "ongoing": 1,
      "phases": [
        "PHASE3",
        "PHASE2"
      ],
      "trials": [
        "NCT00003326",
        "NCT06304974",
        "NCT00493025",
        "NCT00022139"
      ],
      "repurposing_score": 65.0,
      "chembl_id": "CHEMBL428647",
      "max_phase": "4.0",
      "resolution_source": "chembl_exact"
    },
    {
      "drug": "Ramucirumab",
      "total_trials": 2,
      "completed": 1,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2"
      ],
      "trials": [
        "NCT02678182",
        "NCT02539225"
      ],
      "repurposing_score": 60.0,
      "chembl_id": "CHEMBL1743062",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    }
  ],
  "candidate_safety_profiles": [
    {
      "drug_name": "Irinotecan",
      "chembl_id": "CHEMBL481",
      "fda_adverse_events": {
        "top_adverse_events": [
          "Would be retrieved from FDA OpenFDA API"
        ],
        "data_source": "FDA OpenFDA (simulated)",
        "total_reports": "Variable based on drug usage"
      },
      "drug_interactions": [
        "Would be retrieved from RxNav API"
      ],
      "contraindications": [
        "Would be retrieved from FDA drug labels"
      ],
      "mechanism_summary": "Would be retrieved from DrugBank/FDA labels",
      "safety_score": 100.0
    },
    {
      "drug_name": "Paclitaxel",
      "chembl_id": "CHEMBL428647",
      "fda_adverse_events": {
        "top_adverse_events": [
          "Peripheral neuropathy (87%)",
          "Neutropenia (90%)",
          "Myalgia (60%)"
        ],
        "data_source": "FDA OpenFDA (simulated)",
        "total_reports": "Variable based on drug usage"
      },
      "drug_interactions": [
        "CYP2C8 inhibitors",
        "P-glycoprotein substrates"
      ],
      "contraindications": [
        "Neutrophil count <1,500/mm\u00b3",
        "Known hypersensitivity"
      ],
      "mechanism_summary": "Microtubule stabilizing agent - prevents depolymerization",
      "safety_score": 90.0
    },
    {
      "drug_name": "fluorouracil",
      "chembl_id": "CHEMBL185",
      "fda_adverse_events": {
        "top_adverse_events": [
          "Would be retrieved from FDA OpenFDA API"
        ],
        "data_source": "FDA OpenFDA (simulated)",
        "total_reports": "Variable based on drug usage"
      },
      "drug_interactions": [
        "Would be retrieved from RxNav API"
      ],
      "contraindications": [
        "Would be retrieved from FDA drug labels"
      ],
      "mechanism_summary": "Would be retrieved from DrugBank/FDA labels",
      "safety_score": 90.0
    },
    {
      "drug_name": "Capecitabine",
      "chembl_id": "CHEMBL1773",
      "fda_adverse_events": {
        "top_adverse_events": [
          "Would be retrieved from FDA OpenFDA API"
        ],
        "data_source": "FDA OpenFDA (simulated)",
        "total_reports": "Variable based on drug usage"
      },
      "drug_interactions": [
        "Would be retrieved from RxNav API"
      ],
      "contraindications": [
        "Would be retrieved from FDA drug labels"
      ],
      "mechanism_summary": "Would be retrieved from DrugBank/FDA labels",
      "safety_score": 80.0
    },
    {
      "drug_name": "Docetaxel",
      "chembl_id": "CHEMBL3545252",
      "fda_adverse_events": {
        "top_adverse_events": [
          "Would be retrieved from FDA OpenFDA API"
        ],
        "data_source": "FDA OpenFDA (simulated)",
        "total_reports": "Variable based on drug usage"
      },
      "drug_interactions": [
        "Would be retrieved from RxNav API"
      ],
      "contraindications": [
        "Would be retrieved from FDA drug labels"
      ],
      "mechanism_summary": "Would be retrieved from DrugBank/FDA labels",
      "safety_score": 80.0
    }
  ],
  "alternative_targets": [
    {
      "target": "HER2",
      "inhibitor_count": 50,
      "most_potent_ic50": 5.0,
      "most_advanced_compound": {
        "chembl_id": "CHEMBL545315",
        "phase": "3.0"
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 8,
        "completed": 6,
        "failed": 3,
        "phases": {
          "PHASE1": 6,
          "PHASE2": 7,
          "PHASE3": 5
        }
      },
      "literature_count": 10,
      "development_score": 0.79,
      "pdb_structures": [
        {
          "pdb_id": "5TDN",
          "title": "Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces",
          "resolution": 1.63,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "5TDO",
          "title": "Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces",
          "resolution": 1.61,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "5TDP",
          "title": "Crystal structure of the Fab fragment of anti-HER2 antibody 4D5 with redesigned heavy and light chain interfaces",
          "resolution": 1.716,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "2JAB",
          "title": "A designed ankyrin repeat protein evolved to picomolar affinity to Her2",
          "resolution": 1.7,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "6S0N",
          "title": "A9 peptide derived from Herceptin fab binding region",
          "resolution": null,
          "method": "SOLUTION NMR"
        }
      ],
      "rationale": "Targeting HER2 could provide a more personalized approach for patients with HER2-positive esophageal cancer, addressing the limitations of broad immunotherapy and chemotherapy strategies.",
      "confidence": 0.85
    },
    {
      "target": "EGFR",
      "inhibitor_count": 50,
      "most_potent_ic50": 0.45,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 4,
        "completed": 9,
        "failed": 4,
        "phases": {
          "PHASE1": 11,
          "PHASE2": 4,
          "PHASE3": 4
        }
      },
      "literature_count": 10,
      "development_score": 0.78,
      "pdb_structures": [
        {
          "pdb_id": "7OM5",
          "title": "Anti-EGFR nanobody EgB4",
          "resolution": 1.48,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "2XKN",
          "title": "Crystal structure of the Fab fragment of the anti-EGFR antibody 7A7",
          "resolution": 1.4,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "2Z4Q",
          "title": "Crystal structure of a murine antibody FAB 528",
          "resolution": 2.3,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1WT5",
          "title": "The Crystal Structure Of A Humanized Antibody Fv 528",
          "resolution": 2.1,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "8JFQ",
          "title": "Structure of the Major G-Quadruplex in the Human EGFR Oncogene Promoter Adopts a Unique Folding Topology with a Distinctive Snap-back Loop",
          "resolution": null,
          "method": "SOLUTION NMR"
        }
      ],
      "rationale": "EGFR inhibitors could provide an alternative mechanism to target cancer cell proliferation and survival pathways that were not effectively addressed by previous treatments.",
      "confidence": 0.75
    },
    {
      "target": "MET",
      "inhibitor_count": 50,
      "most_potent_ic50": 0.014,
      "most_advanced_compound": {
        "chembl_id": "CHEMBL4303669",
        "phase": "4.0"
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 6,
        "completed": 7,
        "failed": 4,
        "phases": {
          "PHASE1": 1,
          "PHASE2": 3,
          "PHASE3": 1
        }
      },
      "literature_count": 10,
      "development_score": 0.78,
      "pdb_structures": [
        {
          "pdb_id": "1CMB",
          "title": "THREE DIMENSIONAL CRYSTAL STRUCTURES OF ESCHERICHIA COLI MET REPRESSOR WITH AND WITHOUT COREPRESSOR",
          "resolution": 1.8,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "4FO8",
          "title": "Pseudomonas aeruginosa MetAP with Met, in Mn form",
          "resolution": 1.9,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1MJQ",
          "title": "METHIONINE REPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO AN ALTERED MET CONSENSUS OPERATOR SEQUENCE",
          "resolution": 2.4,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1MJO",
          "title": "METHIONINE HOLOREPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO THE MINIMAL MET CONSENSUS OPERATOR WITH THE CENTRAL TA STEP MUTATED TO AT",
          "resolution": 2.1,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1MJ2",
          "title": "METHIONINE REPRESSOR MUTANT (Q44K) PLUS COREPRESSOR (S-ADENOSYL METHIONINE) COMPLEXED TO A CONSENSUS OPERATOR SEQUENCE",
          "resolution": 2.4,
          "method": "X-RAY DIFFRACTION"
        }
      ],
      "rationale": "Targeting MET may help in overcoming resistance mechanisms seen in esophageal cancer, providing a novel approach to treatment.",
      "confidence": 0.7
    },
    {
      "target": "PI3K/AKT/mTOR pathway",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 8,
        "completed": 5,
        "failed": 3,
        "phases": {
          "PHASE1": 7,
          "PHASE2": 12,
          "PHASE3": 3
        }
      },
      "literature_count": 10,
      "development_score": 0.48,
      "pdb_structures": [],
      "rationale": "Inhibiting this pathway could address metabolic dysregulation in esophageal cancer, which was not targeted by previous therapies.",
      "confidence": 0.8
    },
    {
      "target": "CDK4/6",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 8,
        "completed": 7,
        "failed": 1,
        "phases": {
          "PHASE1": 4,
          "PHASE2": 7,
          "PHASE3": 7
        }
      },
      "literature_count": 10,
      "development_score": 0.49,
      "pdb_structures": [
        {
          "pdb_id": "1BD8",
          "title": "STRUCTURE OF CDK INHIBITOR P19INK4D",
          "resolution": 1.8,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1IHB",
          "title": "CRYSTAL STRUCTURE OF P18-INK4C(INK6)",
          "resolution": 1.95,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1IXV",
          "title": "Crystal Structure Analysis of homolog of oncoprotein gankyrin, an interactor of Rb and CDK4/6",
          "resolution": 2.3,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "7SJ3",
          "title": "Structure of CDK4-Cyclin D3 bound to abemaciclib",
          "resolution": 2.51,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "3G33",
          "title": "Crystal structure of CDK4/cyclin D3",
          "resolution": 3.0,
          "method": "X-RAY DIFFRACTION"
        }
      ],
      "rationale": "Inhibiting CDK4/6 could provide a novel strategy to halt cell cycle progression in esophageal cancer cells, addressing the limitations of previous treatments.",
      "confidence": 0.65
    }
  ],
  "failed_trials_sample": [
    {
      "nct_id": "NCT05874726",
      "title": "Biological Sample Repository for Gastrointestinal Disorders",
      "status": "SUSPENDED",
      "phase": [],
      "conditions": [
        "Obesity",
        "Obesity, Morbid",
        "Obesity, Primary",
        "Gastro-Intestinal Disorder",
        "Overweight and Obesity",
        "Overweight",
        "Overweight or Obesity",
        "Diabetes Type 2",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Hypertension",
        "Hyperlipidemias",
        "Sleep Apnea",
        "GERD",
        "Gastroesophageal Reflux",
        "Musculoskeletal Pain Disorder",
        "Cancer"
      ],
      "interventions": [
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Blood Collection",
          "description": "Blood collection via venipuncture"
        },
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Urine Collection",
          "description": "Free catch urine sample collection"
        },
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Tissue Sample Collection",
          "description": "Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned."
        }
      ],
      "start_date": "2023-07-19",
      "completion_date": "2029-04",
      "enrollment": 500,
      "primary_outcomes": [
        {
          "measure": "Serum sample repository",
          "description": "Blood (10 ml) will be collected from the enrolled subjects, serum will be extracted and stored at -80 degrees for up to 10 years.",
          "time_frame": "Change from Baseline to 10 years."
        },
        {
          "measure": "Urine sample repository",
          "description": "Urine (5 ml) will be collected via free catch method and stored at -80 degrees C for up to 10 years.",
          "time_frame": "Change from Baseline to 10 years."
        },
        {
          "measure": "Tissue sample repository",
          "description": "Tissue samples (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) will be collected during a scheduled endoscopic examination. Biopsy tissue will be collected with a large capacity biopsy forceps and deposited into a conical vial containing a freshly prepared balanced salt solution including a HEPES buffer at the bedside, using 5mL of buffered salt solution per 5-10 mm3 of tissue biopsy, at 4 degrees C. Tissue will be stored at -80\u2070C until they are \"used up\" or for up to 10 years from collection.",
          "time_frame": "Change from Baseline to 10 years."
        }
      ],
      "why_stopped": "IRB Approval Lapse - working on resubmission",
      "results_available": false
    },
    {
      "nct_id": "NCT03278626",
      "title": "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma",
      "status": "TERMINATED",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Nivolimumab+Carboplatin/paclitaxel+Radiation",
          "description": "In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction \u00d7 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64))."
        }
      ],
      "start_date": "2017-06-27",
      "completion_date": "2021-05-31",
      "enrollment": 12,
      "primary_outcomes": [
        {
          "measure": "Phase 1: Number of Unacceptable Toxicity (UT) Events",
          "description": "UT is defined as:\n\n1. Recurrent grade 3 or 4 hematologic toxicity (despite 1 prior dose reduction in chemotherapy)\n2. any toxicity that results in a \\> 2-week delay in chemoradiation",
          "time_frame": "92 days (up to 28 days after Day 64)"
        },
        {
          "measure": "Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response)",
          "description": "Clinical and pathological response after neoadjuvant therapy cCR by endoscopic + PET/CT evaluation; pCR for patients undergoing surgery Clinical Complete Response (cCR), no malignancy is found on clinical examination, imaging, endoscopy, and biopsy; Pathological Complete Response (pCR), no invasive and no in situ residual tumors in tissue",
          "time_frame": "5-8 Weeks post radiation treatment (7-8 months after treatment start)"
        }
      ],
      "why_stopped": "The study was stopped earlier than anticipated due to slow accrual",
      "results_available": true
    },
    {
      "nct_id": "NCT02017366",
      "title": "Design of the EFECTS Trial",
      "status": "WITHDRAWN",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "type": "OTHER",
          "name": "Enteral feeding",
          "description": "Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight."
        }
      ],
      "start_date": "2018-10",
      "completion_date": "2022-04",
      "enrollment": 0,
      "primary_outcomes": [
        {
          "measure": "overall survival from day of surgery",
          "description": "overall survival at 5 years after esophagectomy",
          "time_frame": "5 years postoperative"
        }
      ],
      "why_stopped": "adapted protocol with changed outcome measures, changed recruitment number, no submission to ethical board review",
      "results_available": false
    },
    {
      "nct_id": "NCT03975465",
      "title": "EMST and Swallowing in Long-Term Survivors of HNCA",
      "status": "TERMINATED",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Deglutition Disorders"
      ],
      "interventions": [
        {
          "type": "BEHAVIORAL",
          "name": "Expiratory Muscle Strength Training",
          "description": "8 weeks of EMST at 75% maximum expiratory pressure (MEP)"
        },
        {
          "type": "BEHAVIORAL",
          "name": "Pharyngeal Muscle Strengthening Exercises",
          "description": "8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing"
        }
      ],
      "start_date": "2018-09-10",
      "completion_date": "2024-06-04",
      "enrollment": 6,
      "primary_outcomes": [
        {
          "measure": "Level of Oral Intake (number)",
          "description": "Change in Food Level and Drink Level on International Dysphagia Diet Standardisation Initiative (IDDSI) scale will be calculated from baseline to post-treatment.\n\nIDDSI scale rates the level of liquid or food that the person can eat. Scale values range from 0 to 7, with higher values indicating better outcome (greater ability to eat).",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Maximum Expiratory Pressure (MEP) cm H20",
          "description": "Change in maximum expiratory pressure level will be calculated from baseline to post-treatment.",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Extent of hyoid movement (mm)",
          "description": "From Videofluoroscopic Swallow Studies (VFSS), the change in extent of hyoid movement in mm will be determined from baseline to post-treatment.",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Upper esophageal sphincter (UES) opening width (mm)",
          "description": "From Videofluoroscopic Swallow Studies (VFSS), the change in width of UES opening width in mm will be determined from baseline to post-treatment.",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Presence of pharyngeal residue (dichotomous)",
          "description": "From Videofluoroscopic Swallow Studies (VFSS), the presence of residue in the pharynx (yes or no) will be determined from baseline to post-treatment.",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Penetration-Aspiration Scale rating (number)",
          "description": "From Videofluoroscopic Swallow Studies (VFSS), change in the Penetration-Aspiration Scale (PAS) score will be determined from baseline to post-treatment. Penetration-Aspiration Scale is an 8-point ordinal rating scale that rates the depth to which food or liquid invades the airway. Values range from a minimum of 1 to a maximum of 8; higher values represent worse outcome (i.e. greater depth of invasion into the airway)",
          "time_frame": "8 weeks"
        },
        {
          "measure": "Timing of Aspiration (category)",
          "description": "From Videofluoroscopic Swallow Studies (VFSS), timing of aspiration will be determined from baseline to post-treatment. Timing is identified as a category, either before, during, or after.",
          "time_frame": "8 weeks"
        }
      ],
      "why_stopped": "Poor accruals",
      "results_available": false
    },
    {
      "nct_id": "NCT02749526",
      "title": "Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial",
      "status": "TERMINATED",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal"
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "\"Endostar\"",
          "description": "30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
        },
        {
          "type": "DRUG",
          "name": "Liposo",
          "description": "135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
        },
        {
          "type": "DRUG",
          "name": "cisplatin",
          "description": "25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
        },
        {
          "type": "DRUG",
          "name": "Gimeracil and Oteracil Potassium \uff08Tegafur\uff09",
          "description": "40mg bid\uff0cD1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
        }
      ],
      "start_date": "2016-04",
      "completion_date": "2018-12",
      "enrollment": 70,
      "primary_outcomes": [
        {
          "measure": "R0 Resection rate",
          "description": "",
          "time_frame": "up to 8 months"
        }
      ],
      "why_stopped": "low accrual rate",
      "results_available": false
    }
  ],
  "metadata": {
    "timestamp": "2025-07-29T13:10:56.254360",
    "query": {
      "disease": "esophageal cancer",
      "target": null
    },
    "version": "1.0"
  }
}